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Abstract: Arterial calcification, the deposition of calcium-phosphate crystals in the extracellular
matrix, resembles physiological bone mineralization. It is well-known that extracellular nucleotides
regulate bone homeostasis raising an emerging interest in the role of these molecules on
arterial calcification. The purinergic independent pathway involves the enzymes ecto-nucleotide
pyrophosphatase/phosphodiesterases (NPPs), ecto-nucleoside triphosphate diphosphohydrolases
(NTPDases), 5′-nucleotidase and alkaline phosphatase. These regulate the production and breakdown
of the calcification inhibitor—pyrophosphate and the calcification stimulator—inorganic phosphate,
from extracellular nucleotides. Maintaining ecto-nucleotidase activities in a well-defined range is
indispensable as enzymatic hyper- and hypo-expression has been linked to arterial calcification. The
purinergic signaling dependent pathway focusses on the activation of purinergic receptors (P1, P2X
and P2Y) by extracellular nucleotides. These receptors influence arterial calcification by interfering
with the key molecular mechanisms underlying this pathology, including the osteogenic switch and
apoptosis of vascular cells and possibly, by favoring the phenotypic switch of vascular cells towards
an adipogenic phenotype, a recent, novel hypothesis explaining the systemic prevention of arterial
calcification. Selective compounds influencing the activity of ecto-nucleotidases and purinergic
receptors, have recently been developed to treat arterial calcification. However, adverse side-effects
on bone mineralization are possible as these compounds reasonably could interfere with physiological
bone mineralization.
Keywords: arterial calcification; purinergic signaling; pyrophosphate; ecto-nucleotidases;
extracellular nucleotides
1. Introduction
Our genetic code has a well-defined arrangement of building blocks or nucleotides adenosine
5′-triphosphate (ATP), uridine 5′-triphosphate (UTP), cytidine 5′-triphosphate (CTP) and guanosine
5′-triphosphate (GTP) which are translated into proteins. Interestingly, nucleotides are not only located
intracellularly and cells indeed have the capacity to release nucleotides into the extracellular space
through either a controlled release mechanism or via cell death. In the 1970s, Geoffrey Burnstock
discovered that extracellular nucleotides play an important role as signaling molecules [1]. Extensive
research has demonstrated that extracellular nucleotides, mainly ATP and to a lesser extent UTP and
adenosine-5′-diphosphate (ADP), regulate many biological processes including blood coagulation,
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wound healing, inflammation, cancer and bone formation [2–4]. Normally, the basal concentration
of ATP intracellularly is around 3–5 mM while outside the cell the concentration of ATP should be
around 3–500 nM to activate nearby purinergic receptors. Furthermore, extracellular nucleotides have
a short half-life (measured in seconds) due to the close proximity of ecto-nucleotidases or enzymes
which are involved in the breakdown of extracellular nucleotides. This makes that their paracrine
radius is only a few hundred microns [5]. Numerous studies have shown that extracellular nucleotides
influence bone remodeling, acknowledged by multiple reviews [6–8]. Interestingly, due to the striking
similarities between physiological bone formation and pathological arterial calcification, there is an
emerging interest in the role of extracellular nucleotides in pathological mineralization in the vessel
wall which will be discussed in detail in the next paragraphs.
2. Arterial Calcification
Arterial calcification, or the accumulation of calcium-phosphate crystals (i.e., hydroxyapatite) in
the arterial wall or valves, has a significant impact on morbidity and mortality in chronic kidney disease
(CKD), osteoporosis and diabetes patients by provoking severe cardiovascular events [9]. Four types of
arterial calcification can be distinguished according to their location being (i) calcification in the intimal
layer of the arterial wall in association with atherosclerotic plaques or arterial intima calcification, (ii)
calcification in the medial layer of the arterial wall, called arterial media calcification or Monckeberg’s
arteriosclerosis, (iii) aortic valve calcification and (iv) calciphylaxis or calcific uremic arteriolopathy or
calcification of the small blood vessels in the skin. Each subtype of arterial calcification has its own
specific risk factors and outcomes, shown in Figure 1 adapted from [10–12].
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fetuin-A) [14,15], (ii) gain of circulating calcification stimulators (i.e., hyperphosphatemia, 
hypercalcemia and uremic toxins) [15,16] and (iii) the ability of vascular cells, i.e., vascular smooth 
muscle cells (VSMCs) in the (medial or intimal) arterial wall or valve interstitial cells (VICs) in aortic 
valves, to transdifferentiate into bone-like cells which goes along with upregulation of 
osteo/chondrogenic marker genes such as Runt-related transcription factor 2 (Runx2), tissue non-
Figure 1. General mechanism and subtypes of arterial calcification. (Panel A) Describes the general
mechanisms of arterial calcification. (Panel B) An overview of the risk factors, specific mechanisms and
clinical consequences of arterial intima/media calcification, aortic valve calcification and calciphylaxis.
VSMC: vascular smooth muscle cell, VIC: valve interstitial cell, Vascular cell: covers VSMCs, VICs and
endothelial cells.
Furthermore, cardiac calcification at the mitral annulus is a process possessing characteristics of
both atherosclerotic plaque calcification and media calcification [13]. In general, the process of arterial
calcification has three important pathological characteristics (i) loss of circulating calcification inhibitors
(i.e., pyrophosphate (PPi), (vitamin K-dependent) carboxylated matrix gla protein and fetuin-A) [14,15],
(ii) gain of circulating calcification stimulators (i.e., hyperphosphatemia, hypercalcemia and uremic
toxins) [15,16] and (iii) the ability of vascular cells, i.e., vascular smooth muscle cells (VSMCs) in the
(medial or intimal) arterial wall or valve interstitial cells (VICs) in aortic valves, to transdifferentiate
into bone-like cell which goes along with upr gulation of osteo/chondro enic marker enes such as
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Runt-related transcription factor 2 (Runx2), tissue non-specific alkaline phosphatase (TNAP), Bone
morphogenetic protein 2 (BMP2) and SRY-Box transcription factor 9 (Sox9). These bone-like cells
produce and release calcified matrix vesicles, in which calcium and phosphate is built up, into the
extracellular matrix resulting into mineralization of the surrounding tissue [15,16]. Besides VSMCs
and VICs, endothelial cells also play a crucial role in the process of arterial calcification by (i) the
release of nitric oxide (NO) and (ii) undergoing endothelial to mesenchymal transition. Results
from in vitro and in vivo studies form an argument for the fact that NO inhibits VSMC calcification
and osteo/chondrogenic transdifferentiation. Endothelial to mesenchymal transition contributes to
arterial calcification by the generation of mesenchymal stem-like cells that can eventually migrate
to the medial layer and differentiate further into multiple cell lineages: fibroblasts/myofibroblasts,
osteoblasts/osteocytes and chondrocytes [17].
Extracellular nucleotides, such as ATP and UTP, potently inhibit this extracellular matrix
mineralization via dual inhibitory pathways (Figure 2): (i) via their hydrolysis product PPi, which
binds to hydroxyapatite crystals and prevents further incorporation of inorganic phosphate (Pi) into the
crystals (purinergic receptor independent pathway) and (ii) by directly activating purinergic receptors
(purinergic receptor dependent pathway). Furthermore, ATP and UTP are involved in purinergic
receptor signaling (purinergic receptor dependent pathway) and are hydrolyzed by ecto-nucleotidases
to generate PPi (purinergic receptor independent pathway), while the extracellular nucleotides CTP
and GTP are only involved in the purinergic receptor independent pathway, as they do not interact with
purinergic receptors [18]. This review will discuss the role of both the purinergic receptor independent
and dependent pathways in arterial calcification.
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3. Purinergic Receptor Independent Pathway
PPi is a key player in the purinergic receptor independent pathway as it is one of the most powerful
endogenous calcification inhibitors which binds to nascent hydroxyapatite crystals thereby preventing
further incorporation of Pi into these crystals [19]. The family of ecto-nucleotidases play an indispensable
role in regulating the production and breakdown of PPi and Pi, both controlling the mineralization
processes, from extracellular nucleotides. Four families of ecto-nucleotidases are distinguished, being:
(1) ecto-nucleotide pyrophosphatase/phosphodiesterases (NPPs); (2) ecto-nucleoside triphosphate
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diphosphohydrolases (NTPDases); (3) 5′-nucleotidase, and (4) alkaline phosphatase [20]. Maintaining
a proper plasma PPi/Pi ratio is critical as (i) lower plasma PPi in e.g., dialysis patients negatively
correlates with arterial calcification [21], (ii) multiple animal models have shown that an increase in
plasma PPi inhibits arterial calcification [22–25] and (iii) oral administration of PPi to healthy volunteers
recently resulted in a transient elevation of plasma PPi, indicating that oral PPi supplementation might
be a promising therapy for the treatment of arterial calcification in particular patient population such as
infants who suffer from arterial calcification and low levels of plasma PPi, a disorder called generalized
arterial calcification of infancy [26]. The next paragraphs will discuss the involvement of the different
ecto-nucleotidases, controlling the plasma PPi/Pi ratio, in the calcification process of the arterial wall.
3.1. Involvement of NPPs in Arterial Calcification
NPPs are plasma membrane proteins known to hydrolyze a wide range of phosphodiester
bonds, e.g., nucleoside triphosphates, (cyclic) dinucleotides, and nucleotide sugars [20]. Seven
subtypes of NPPs (NPP1–7) exist whereby NPP1 and NPP3 are suggested to play a role in the arterial
calcification process. NPP1 stimulates the hydrolysis of ATP into AMP and PPi however it has also
been implicated, to a lesser extent, in generating Pi [27]. Generalized arterial calcification of infancy,
an autosomal-recessive genetic disorder, causes the premature onset of arterial calcification due to a
functional absence of the NPP1-encoding gene (ENPP1) leading to a decrease in NPP1 activity and
thus a reduction in the generation of PPi. This was also confirmed in an ENPP1 knockout mouse
model that mimics this disease phenotype and leads to the development of arterial calcification [28].
Moreover, NPP1 enzyme replacement therapy prevented the development of arterial calcifications
in a mouse model of generalized arterial calcification of infancy [29]. Similarly, pseudoxanthoma
elasticum, which is characterized by the development of ectopic calcification of soft connective
tissues, is associated with ENPP1 missense variants [30]. Alternatively, an overexpression of NPP1
activity is also linked to ectopic calcification because it (i) triggers TNAP activity (discussed in detail
below) to produce Pi in order to restore the PPi/Pi ratio and (ii) depletes the ATP pool leading to a
reduction in purinergic receptor signaling (discussed in detail below) [31]. NPP1 inhibitors have been
developed as potential therapeutics for diabetes mellitus and brain cancers [32]. Additionally, a recent
in vitro study showed that treating mineralized VICs—which overexpress NPP1—with a specific
non-competitive NPP1 inhibitor led to a significant (p < 0.05) decrease in mineral content, apoptosis
and osteo/chondrogenic transdifferentiation, as compared to VICs on a pro-calcifying medium without
inhibitor supplementation [33]. In conclusion, it is key to maintain the NPP1 activity in a well-defined
range as overexpression, as well as reduced expression of NPP1 activity, have been linked to arterial
calcification. Furthermore, NPP3, an enzyme that is also known as basophil-specific ecto-enzyme
E-NPP3 (CD203c) is involved in the allergic inflammation response. Basophils are activated by the
binding of an antigen to an immunoglobulin E, favoring the release of inflammatory mediators
and upregulation of NPP3 to the cell surface. Subsequently, NPP3 upregulation induces hydrolysis
of extracellular ATP, a pro-inflammatory mediator, leading to the suppression of chronic allergic
inflammation [34]. With regard to its role in arterial calcification, a study by Villa-Bellosta et al.
suggests that in VSMCs, NPP3 also participates in PPi hydrolysis [35].
In conclusion, both absence/reduced presence and overexpression of NPP1 can induce arterial
calcification, implying that keeping its activity in a well-defined molecular range is crucial. Furthermore,
the role of NPP3 in the arterial calcification process has to be further investigated.
3.2. Involvement of Alkaline Phosphatase in Arterial Calcification
Four types of alkaline phosphatase exist including three tissue-specific isozymes intestinal,
placental and germ-cell alkaline phosphatase and TNAP [20]. In human plasma, 95% of the alkaline
phosphatase activity is attributed to the TNAP isozyme which is mainly expressed by the liver,
kidney and bone [36]. In the liver and kidney, TNAP plays a pivotal role in anti-inflammatory
actions through dephosphorylation of the bacterial endotoxin lipopolysaccharide and probably by
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depletion of the ATP pool, released during cell stress, as ATP attracts phagocytes and platelets and
activates the nucleotide-binding leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3)
inflammasome [37]. While in the bone, TNAP is produced by osteoblasts to maintain adequate
bone mineralization by the degradation of PPi into Pi [7]. Similar to this, VSMCs are capable of
expressing TNAP under osteogenic circumstances to promote the calcification process [15]. TNAP is
loaded into calcified matrix vesicles under control of the sorting receptor sortilin, thereby favoring
the aggregation/accumulation of calcium-phosphate crystals [38]. A recent study has suggested that
TNAP is potentially cleaved from the calcified matrix vesicles just before binding to the extracellular
matrix as TNAP disturbs interactions between annexin a5, a collagen-binding protein present in the
calcified matrix vesicles, and the extracellular matrix [39]. Furthermore, endoplasmic reticulum stress
induced during arterial calcification, regulates alkaline phosphatase mRNA production and activity in
VSMCs by interacting with the activating transcription factor 4 (ATF4) [40]. Interestingly, apabetalone,
a recently introduced novel inhibitor of bromodomain and extraterminal (BET) proteins which binds
to transcription factors to regulate gene expression, has been suggested to disrupt the interaction
between BET protein 4 and an activating transcription factor 3 (ATF3) [41]. Moreover, apabetalone
decreased major adverse cardiac events in cardiovascular disease patients [42] and significantly
(p < 0.02) diminished circulating alkaline phosphatase levels in CKD patients versus CKD patients
treated with a placebo [43]. Additionally, apabetalone blocked transdifferentiation and calcification of
VSMCs through halting the TNAP gene expression, protein levels and enzyme activity [41].
In hemodialysis patients, serum TNAP levels have been associated with significantly increased
coronary artery calcium scores (OR 3.89, 95% CI (2.01; 7.54), p = 0.001) and abdominal aortic
calcification (r = 0.389; p < 0.01) [44,45]. Moreover, transgenic mouse models in which TNAP
was selectively over-expressed in either VSMCs or endothelial cells led to the development of
arterial media calcifications [46,47]. On the contrary, low levels of TNAP activity induce a state
of hypophosphatasia, characterized by fractures, arthralgia and neurological complications [48].
Consequently, it is essential to maintain the level of TNAP activity in a well-defined molecular
range, also observed for NPP1 activity (see above). In this respect, investigating the cut-off values
of the ecto-nucleotidase enzyme activities in plasma/serum could be interesting to predict adverse
outcomes including arterial calcification. In conclusion, influencing the activity of TNAP would be
an eligible therapeutic approach for arterial calcification and as such will stimulate the discovery of
selective and potent TNAP inhibitors. The first inhibitors were non-selective inhibitors of alkaline
phosphatase, acting through uncompetitive or competitive interactions with the enzyme. For example,
L-phenylalanine, imidazole, histamine, and theophylline are uncompetitive inhibitors whilst phosphate,
phosphoethanolamine, and phenylphosphonate inhibit alkaline phosphatase competitively [49]. Later
on, selective, uncompetitive inhibitors against TNAP were developed which can be classified into three
groups (i) series of sulfonamide inhibitors [50], (ii) series of triazolyl pyrazole inhibitors [51] and (iii)
series of coumarin sulphonate inhibitors [52]. Multiple studies have proven that the selective TNAP
inhibitor 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425) is an effective therapy
against arterial calcification in multiple mouse and rat models for arterial media calcification and
pseudoxanthoma elasticum [46,47,53–55]. With regard to physiological bone mineralization, treatment
with SBI-425 went along with a decreased bone formation rate and increased osteoid maturation time
in a rat model with warfarin-induced arterial calcification [55] and which was not seen in previous
mouse studies [46,53,54]. For this reason, investigating the therapeutic effect of SBI-425 in other species,
large skeletally mature animals including dogs and rabbits who have a bone structure highly similar to
that of humans, is indispensable [56], in particular given the knowledge that CKD patients, who are a
major target population for treating arterial calcification, already suffer from bone metabolic defects.
Lastly, orphan phosphatase 1 (PHOSPHO1) relates closely to the family of alkaline phosphatases.
PHOSPHO1 initiates the hydrolysis of intravesicular metabolites including phosphoethanolamine and
phosphocholine to obtain Pi. Thus, it has been suggested that PHOSPHO1 functions synergistically
with TNAP to accumulate Pi into the calcified matrix vesicles [57]. Moreover supplementation of a
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PHOSPHO1 inhibitor alone and in combination with a TNAP inhibitor, prevented in vitro VSMC
calcification [58].
In conclusion, targeting TNAP activity to treat arterial calcification has received a lot of interest.
However, similarly to NPP1 activity, monitoring TNAP activity in the circulation is necessary as too
high levels of TNAP activity correlate to the development of arterial calcification while too low levels
associate with bone mineralization defects and neurological defects.
3.3. Involvement of NTPDases and 5′-Nucleotidase in Arterial Calcification
The NTPDases or CD39 superfamily contains eight members including the cell surface NTPDase
1–3,8 and the intracellular NTPDase 4–7 which catalyze the hydrolysis of ATP/ADP into ADP/AMP
under the formation of Pi. Furthermore, 5′-nucleotidase or CD73 produces adenosine by the hydrolysis
of AMP [59]. Studies have shown that the activity of NTPDase 1 and 5′-nucleotidase was significantly
(p < 0.05) lower in calcified aortic valves versus non-calcified aortic valves suggesting a potential role of
both ecto-nucleotidases in aortic valve calcification [60,61]. Moreover, ARL67156, an NTPDase inhibitor,
however also a non-specific purinergic P2 receptor inhibitor, prevented the development of aortic
stenosis and calcification of the aorta and aortic valves in a warfarin rat model [62]. In addition, a recent
study showed that a combination therapy of ATP, the TNAP inhibitor—levamisole, and NTPDase
inhibitor—ARL67156, reduced arterial calcification and extended longevity in a Hutchinson–Gilford
progeria syndrome mouse model, which was accomplished by increasing the PPi production through
preventing (i) TNAP mediated hydrolysis of PPi into Pi and (ii) NTPDase mediated reduction in
the availability of extracellular ATP for PPi production by NPPs. Hutchinson–Gilford progeria
syndrome is a rare genetic disorder observed in children who suffer from premature aging and
cardiovascular disease including vascular stenosis and excessive arterial calcification [63]. Until
today, little information on the role of the different subtypes of NTPDases in arterial calcification
exists, probably due to a lack of specific synthetic NTPDase inhibitors. A rare disease called arterial
calcifications due to deficiency of 5′-nucleotidase/CD73 (ACDC), caused by autosomal recessive
mutations in the CD73-encoding gene (NT5E), is characterized by painful calcification in the arteries
and joints of the lower extremities [64]. Interestingly, osteogenic stimulation of induced pluripotent
stem cell-derived mesenchymal stromal cells from ACDC patients caused significantly (p < 0.001, after
21 days versus control human dermal fibroblasts) higher levels of TNAP resulting in lower levels of PPi
and activation of the Akt/mammalian target of rapamycin (mTOR) pathway—an arterial calcification
stimulating pathway [65]. Additionally, a study using primary dermal fibroblasts obtained from ACDC
patients demonstrated that the absence of 5′-nucleotidase activity induced a decrease in adenosine
production. The subsequent reduction in adenosine-mediated purinergic P1 receptor signaling and
intracellular cyclic adenosine monophosphate (cAMP), led to activation of the Akt/mTOR pathway.
Subsequently, phosphorylated Akt stimulates the nuclear translocation of the transcription factor
forkhead box O1 protein (FOXO1) to promote the expression and activity of TNAP and thus stimulates
the arterial calcification process [66]. Additionally, adenosine derived from 5′-nucleotidase activity
influences the arterial calcification process by interacting with purinergic P1 receptors, which will also
be discussed in more detail below. In conclusion, the different types of ecto-nucleotidases are closely
entwined in the arterial calcification process shown in Figure 3.
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deficiency or overexpression of NPP1 activity leads to arterial calcification, as well as overexpression of
NPP1 favoring T AP activity and inducing less ATP mediated purinergic receptor 2 signaling (P2R).
(Green) A deficiency of TNAP activity is linked to neurological defects and fracture risk by decreased
Pi generation, while overexpression of TNAP activity favors arterial calcification through a reduction in
PPi. (Orange) A deficiency of CD73 or 5′-nucleotidase triggers arterial calcification by promoting TNAP
activity and reducing the production of adenosine and thus less adenosine mediated P1R signaling.
(Red) Inhibition of NTPDase 1 reduces arterial calcification by diminishing Pi generation. This scheme
is based on the results in multiple cell types including VSMCs, VICs and endothelial cells but also
i.e., primary dermal fibroblasts from arterial calcifications due to deficiency of 5′-nucleotidase/CD73
(ACDC) patients.
4. Purinergic Receptor Dependent Pathway
Once nucleotides and nucleosides are released in the extracellular space, they have the ability
to bind to purinergic ec tors. Two bro d family types of purinergic receptors exist, being P1
and P2 receptors. The G protein-coupled P1 receptor family contains four subtypes A1, A2A, A2B
and A3 which are activated by adenosine. The P2 receptor family can be further subdivided into
eight G protein-coupled P2Y receptors (P2Y1,2,4,6,11,12,13,14) and seven ligand-gated ion channels, the
P2X receptors (P2X1–7) [67,68]. Purinergic signaling plays an important role in regulating both
osteoblast mediated mineralization and osteoclast mediated resorption of the bone matrix [3,18,69].
As already mentioned, the pathological process of arterial calcification mimics physiological bone
mineralization. Consequently, the ability of purinergic receptors to influence ectopic mineralization
has become an area of interest. The research group of Schuchardt et al. was one of the first to provide
evidence for the involvement of P2 receptors in the arterial calcification process. Upon shear stress and
hypoxia, endothelial cells release the contracting factor uridine adenosine tetraphosphate (Up4A) which
stimulates the P2X and P2Y receptors on VSMCs, leading to a phenotypic switch into osteoblast-like
cells with upregulation of alkaline phosphatase and Runx2 [70]. However Up4A is not a selective P2
receptor agonist and only weakly activates some P2 receptors, therefore results need to be interpreted
with caution. Patel. et al. showed that the inhibitory effect on VSMC calcification mediated by ATP and
UTP is not solely attributed to its breakdown product PPi and also involves P2 receptor activation [71].
The mRNA expression of the P2X1, P2X2, P2X4, P2X5, P2X6, and P2Y2 receptors was increased by up
to three times in calcifying VSMCs compared to control VSMCs suggesting a potential role in ectopic
mineralization [71]. The next paragraphs will discuss in depth the involvement of P1 and P2 receptors
in arterial calcification.
4.1. Involvement of P1 Receptors in Arterial Calcification
Adenosine, the endogenous ligand of P1 receptors (A1, A2A, A2B and A3), induces opposing effects
depending on the tissue and activation of its receptor subtype. In general, the activation of A1 and
A3 receptor subtypes reduce intracellular cAMP, whilst triggering theA2A and A2B receptor subtypes
induces the opposite effect [72]. Elevated cAMP signaling and high Pi levels synergistically stimulate
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in vitro VSMC calcification [73]. In line with these results, activation of the A2A receptor promoted
the mineralization process in VIC cultures by favoring the cAMP/protein kinase A pathway, while
activation of the A1 receptor resulting in decreased cAMP levels, inhibited VIC mineralization [31].
Moreover, adenosine treatment of mice aortic roots exposed to an osteogenic medium attenuated
mineralization by A1 and A2B receptor activation, whereas the A2A receptor had an opposite effect on
aortic root mineralization [74]. Recently, an in vitro study using human aortic smooth muscle cells
demonstrated that triggering the A3 receptor resulted in a reduction in matrix mineralization, probably
by decreasing alkaline phosphatase activity [75]. Furthermore, adenosine also plays a role in the
lineage-specific differentiation of mesenchymal stem cells into osteoblasts and adipocytes mediated by
upregulation of the A2A receptor and A1/A2B receptor, respectively [76]. Interestingly, adipocyte-related
protein peroxisome proliferator-activated receptor-gamma (PPARgamma) blocks VSMC calcification
by suppressing Wnt/β-catenin signaling mediated osteo/chondrogenic transdifferentiation [77–79].
This raises the idea that favoring the VSMC phenotypic switch towards an adipogenic phenotype
instead of an osteoblastic phenotype, might be beneficial to counteract arterial calcification. However,
more extensive research is needed to confirm this theory. Furthermore, the process of endothelial
cells undergoing an endothelial to mesenchymal transition, a subtype of epithelial to mesenchymal
transition, has been associated with arterial calcification in mice lacking the matrix gla protein [80].
Interestingly, activation of both P1 and P2 receptors (discussed below) play a significant role in the
epithelial to mesenchymal transition in different pathologies [81]. However, investigating the role of
purinergic receptor signaling in endothelial to mesenchymal transition in endothelial cells and arterial
calcification, would be a novel and interesting route to explore. Taken together, the effect of adenosine
on the arterial calcification process depends on the activated P1 receptor subtype and thus limits the
therapeutic use of adenosine for treating arterial media calcification. Developing synthetic selective P1
receptor subtype agonist/antagonists, however, might be a strategy to tackle the arterial calcification
process. Figure 4 gives an overview of the different P1 receptors in the arterial calcification process.
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alkaline phosphatase (TNAP) activity and cAMP production. Both A1 and A2B receptors might
favor a phenotypic switch of vascular cells into an adipocyte phenotype and by this prevent the
transdifferentiation towards a bone-like phenotype, thus halting the arterial calcification process.
Dashed lines represent relevant findings in other cell-types, not yet shown in vascular cells. The term
vascular cell covers vascular smooth muscle cells and valve interstitial cells.
4.2. Involvement of the P2Y Receptors in Arterial Calcification
The P2Y2 receptor is the most extensively studied purinergic receptor in the context of arterial
calcification. Coté et al. showed that treatment of calcified VICs with a selective P2Y2 receptor agonist,
2-thioUTP, resulted into a reduction in mineralization which was associated with the activation of the
phosphoinositide 3-kinase (PI3K) signaling pathways preventing VIC apoptosis [82]. In agreement,
another study demonstrated that stimulating the P2Y2 receptor in VICs with 2-thioUTP induced the
PI3K signaling pathway. This inhibited NFkB signaling and led to the suppression of IL-6 expression,
a calcification stimulator which acts by its ability to upregulate the osteogenic transcripts Runx2
and BMP2 [83]. Furthermore, these results were reinforced by an in vivo study where mice already
suffering from calcific aortic valve stenosis were treated with intraperitoneal injections of saline or
2 mg/kg body weight/day 2-thioUTP. Interestingly, researchers observed a significant improvement
in left ventricular function (p = 0.0002 versus saline treatment), less left ventricular hypertrophy (p =
0.02 versus saline treatment) and a decrease in aortic valve mineral content (p = 0.006 versus saline
treatment) after two months of 2-thioUTP treatment, without side-effects on the bone mineral content.
The 2-thioUTP mediated regression of calcification of the aortic valve was attributed to acidification of
the extracellular space by upregulation of carbonic anhydrase [84]. These results were very exciting as
regression of ectopic calcification is rarely observed, certainly, without inducing deleterious effects
on bone metabolism. Furthermore, apolipoprotein E knockout mice, susceptible to the development
of arterial intima calcification, with a P2Y2 receptor knockout background developed significantly (p
< 0.001) more extensive calcification in the intima layer as compared to apolipoprotein E knockout
mice expressing the P2Y2 receptor [85]. In contrast, an in vitro study using cells from P2Y2 knockout
mice, found no involvement of the P2Y2 receptor in the calcification of VSMCs [71], the key players in
arterial media calcification and intimal atherosclerotic plaque calcification. This suggests that different
mechanisms are in place according to the location of calcifications in the arterial tree.
Arterial media calcification is associated with arterial stiffening. A vicious cycle of arterial
stiffness and arterial media calcification is described in which mechano-sensing plays an important
role as VSMCs sense matrix stiffness, which in turn induces alterations in gene expression and thus,
stimulates the phenotypic conversion of VSMCs [17]. Interestingly, activation of the P2Y2 receptor has
been associated with mechano-sensing in osteoblasts and chondrocytes [86–88]. During mechanical
loading, stimulating the bending of bones and matrix deformation, a pressure gradient is built up in the
interstitial fluid. Osteocytes are connected by narrow channels, canaliculi, through which the interstitial
fluid has to be squeezed, creating a high wall shear stress within these channels [89]. This fluid shear
stress triggers an extracellular calcium influx, by activation of mechanosensitive and voltage-sensitive
calcium channels, leading to extracellular release of ATP and UTP from vesicles stored in the osteoblast.
Both nucleotides activate the P2Y2 receptor mediated RhoA/Rock pathway resulting in the formation
of actin stress fibers and thus modifying osteoblast stiffness [86]. Similarly to this, vascular wall
shear stress initiates the release of ATP by endothelial cells stimulating the P2Y2 receptor which is
followed by the activation of endothelial nitric oxide synthase (eNOS) [90]. Additionally, another
study indicated that P2Y1, P2Y2 and potentially P2Y4 receptors activate phospholipase C leading to
the production of inositol trisphosphate (IP3) and diacylglycerol, favoring protein kinase C activation
and the release of intracellular calcium stores, ultimately leading to the phosphorylation/activation of
eNOS in endothelial cells [91]. NO induces vasodilatation through relaxation of the VSMCs. Several
studies have shown that NO limits the development of arterial calcification [92–94], indicating that the
interplay between endothelial cells and VSMCs, in part through the P2Y2 receptor, is important to halt
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the calcification process in the arterial wall. Taken together, studies have demonstrated that triggering
the P2Y2 receptor inhibits intima and aortic valve calcification (i) directly by acting on the vascular cell
through halting apoptosis, expressing IL6 and stimulating the resorption of minerals by an acidification
process, (ii) indirectly by probably stimulating endothelial cell mediated NO production. The role of
the P2Y2 receptor in arterial media calcification remains inconclusive and demands further research.
At present, information about the involvement of other P2Y receptor subtypes in the arterial
calcification process is limited. Studies have shown that the P2Y1, P2Y4, P2Y6 and P2Y12 receptors are
involved in the regulation of bone cell function. For example, overexpression of the P2Y1 receptor in
human spinal ligament cells induced mineralization and favored the expression of osteogenic marker
genes BMP2 and Sox9 which was obviated by a selective P2Y1 receptor antagonist [95]. Furthermore,
UDP mediated P2Y6 receptor activation triggered the formation of osteoclasts from precursor cells [96].
Therefore one may assume that engagement of the P2Y6 receptor promotes the transdifferentiation of
VSMCs into bone-resorbing cells and by this method, reverses the calcification process in the arterial
wall. Several studies showed the possibility of reversibility of arterial calcification [97–99]. Lastly,
clopidogrel, a selective P2Y12 receptor antagonist, halted mineralized bone nodule formation, alkaline
phosphatase activity and collagen formation while stimulating adipocyte formation in osteoblast cell
cultures [100]. Additionally, adipogenic differentiation of human bone marrow-derived mesenchymal
stem cells was stimulated by the activation of the P2Y1 and P2Y4 receptor [101]. Knowing this, it
will be interesting to evaluate whether the P2Y1, P2Y4 and P2Y12 receptors might regulate VSMCs
transdifferentiation into an adipogenic phenotype (as discussed in the paragraph above dealing with
the P1 receptors) to prevent arterial calcification. As such, in vitro and subsequently in vivo evaluation
of these alternative P2Y receptors on arterial calcification would be of interest to establish novel,
innovative treatments for arterial calcification. Although, an important remark is that P2 receptors have
overlapping specificity, i.e., the P2Y4 receptor has an overlapping agonist profile with the P2Y2 receptor.
Therefore it is likely that there is a degree of redundancy in the purinergic system, thus inhibiting a
specific P2 receptor may stimulate another P2 receptor to compensate for its loss of function. Figure 5
shows an overview of the involvement of P2Y receptors in arterial calcification.
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3-kinases (PI3K) resulting in a reduction in vascular cell apoptosis and halting the bone-like phenotypic
switch of vascular cells via less NFkB signaling and IL6 production and (ii) favoring carbonic anhydrase
(CA) expression, catalyzing the reaction of water (H2O) and carbon dioxide (CO2) into hydrogen
carbonate (HCO3−) and hydrogen ions (H+) leading to extracellular acidification and thus, resorption
of the calcium-phosphate crystals. The P2Y1 receptor might stimulate the arterial calcification process.
P2Y12 receptor blockage by clopidogrel potentially halts arterial calcification trough inhibition of tissue
non-specific alkaline phosphatase (TNAP) and favoring the transdifferentiation of the vascular cell
towards an adipocyte phenotype, thus preventing a bone-like phenotypic switch. P2Y4 receptor might
also be involved in the phenotypic switch of vascular cells to an adipocyte phenotype. Dashed lines
represent relevant findings in other cell-types, not yet shown in vascular cells. The term vascular cell
covers vascular smooth muscle cells and valve interstitial cells.
4.3. Involvement of the P2X Receptors in Arterial Calcification
With regard to the P2X receptors, research is predominantly focused on the role of the P2X7 receptor
in the process of mineralization. However, its exact function remains inconclusive as published studies
are conflicting. Multiple reports have shown that activation of the P2X7 receptor favors the osteogenic
differentiation of multiple cell types including human mesenchymal stem cells [102], rat calvarial
cells [103], human osteosarcoma cancer cells [104] and bone marrow-derived mesenchymal stem
cells [105,106]. Additionally, activation of the P2X7 receptor on endothelial cells enhances apoptotic
events [107] and thus, might stimulate the arterial calcification process as apoptotic bodies are attractive
nucleation sites for calcium-phosphate crystals. However, Orriss et al. demonstrated that exposing
osteoblasts to a P2X7 receptor agonist, Bz-ATP, or P2X1 and P2X3 receptor agonists, α,β-meATP and
β,γ-meATP, significantly inhibited bone mineralization (p < 0.001 versus control ((without agonist
supplementation) osteoblast) and alkaline phosphatase activity (p < 0.05 versus control ((without
agonist supplementation) osteoblast) [108]. Moreover, a recent study has shown that these agonists
inhibit VSMC calcification in vitro by diminishing VSMC apoptosis and osteo/chondrogenic switch.
Nevertheless these observed inhibitory effects on VSMC calcification were not prevented by the
use of selective P2X receptor antagonists, PPADS (non-selective), NF110 (P2X3), 5-BDBD/PSB-12062
(P2X4) and A740003/AZ10606120 (P2X7), indicating the activation of P2X receptor-independent
mechanisms [109]. Hence, the exact mechanism by which Bz-ATP, α,β-meATP and β,γ-meATP
inhibit VSMC calcification remains unclear. So far, nobody else has investigated the involvement
of P2X receptors in arterial calcification. Interestingly, high levels of extracellular magnesium halt
matrix mineralization of tendon-derived stem cells by suppressing the expression of P2X4, P2X5
and P2X7 receptor and activating the expression of the P2Y1, P2Y2, P2Y4 and P2Y14 receptors [110].
Several studies demonstrated a relationship between dietary magnesium and the prevention of arterial
calcification through inhibiting osteo/chondrogenic transdifferentiation of VSMCs and stopping the
maturation process of amorphous calcium-phosphate particles into stable hydroxyapatite crystals [111].
Taken together, magnesium might also inhibit arterial calcification by regulating the above mentioned
P2 receptors in the arterial wall, however this needs to be further investigated.
In conclusion, purinergic signaling, as well as ecto-nucleotidases play an indispensable role
in the arterial calcification process. Novel therapeutic approaches were developed to treat arterial
calcification including selective TNAP and NPP1 inhibitors as well as synthetic ATP analogues (i.e.,
2-thioUTP, Bz-ATP, α,β-meATP and β,γ-meATP). Based on the recent literature, these treatments have
promising beneficial outcomes on arterial calcification. However, the role of purinergic signaling in the
regulation of these processes is by no means fully defined and further in vitro and in vivo studies are
warranted to elucidate the mechanisms involved. Moreover, awareness for possible side-effects at the
level of the bone is imperative, as possible interference of these compounds with physiological bone
mineralization cannot be excluded. This consideration is of particular importance to CKD patients, a
major target group for treatment of arterial calcification which inherent to their disease state, already
suffer from compromised bone metabolism. Having this in mind, it needs to be emphasized that in
order to obtain safe and efficient therapies against arterial calcification, future research should focus on
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developing novel routes of administration for these compounds thereby solely targeting the vessels
and not the bone compartment.
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